These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31292709)

  • 21. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
    Benucci M; Gobbi FL; Bandinelli F; Damiani A; Infantino M; Grossi V; Manfredi M; Parisi S; Fusaro E; Batticciotto A; Sarzi-Puttini P; Atzeni F; Meacci F
    Immunol Res; 2017 Feb; 65(1):419-422. PubMed ID: 27449503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
    Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
    Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
    Smolen JS; Choe JY; Prodanovic N; Niebrzydowski J; Staykov I; Dokoupilova E; Baranauskaite A; Yatsyshyn R; Mekic M; Porawska W; Ciferska H; Jedrychowicz-Rosiak K; Zielinska A; Choi J; Rho YH
    Rheumatology (Oxford); 2017 Oct; 56(10):1771-1779. PubMed ID: 28957563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
    Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
    Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.
    Park MC; Matsuno H; Kim J; Park SH; Lee SH; Park YB; Lee YJ; Lee SI; Park W; Sheen DH; Choe JY; Choi CB; Hong SJ; Suh CH; Lee SS; Cha HS; Yoo B; Hur JW; Kim GT; Yoo WH; Baek HJ; Shin K; Shim SC; Yang HI; Kim HA; Park KS; Choi IA; Lee J; Tomomitsu M; Shin S; Lee J; Song YW
    Arthritis Res Ther; 2019 May; 21(1):122. PubMed ID: 31113455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): Study protocol for an interventional, multicenter, open-label, single-arm and noninferiority clinical trial with clinical, ultrasound, and biomarker assessments.
    Kawashiri SY; Shimizu T; Sato S; Morimoto S; Kawazoe Y; Sumiyoshi R; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e21151. PubMed ID: 32791688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A; Gharibdoost F; Vojdanian M; Soroosh SG; Soroush M; Ahmadzadeh A; Nazarinia MA; Mousavi M; Karimzadeh H; Shakibi MR; Rezaieyazdi Z; Sahebari M; Hajiabbasi A; Ebrahimi AA; Mahjourian N; Rashti AM
    Arthritis Res Ther; 2017 Jul; 19(1):168. PubMed ID: 28728599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
    Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW
    Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.
    Baji P; Péntek M; Czirják L; Szekanecz Z; Nagy G; Gulácsi L; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S53-64. PubMed ID: 24832836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
    Genovese MC; Glover J; Greenwald M; Porawska W; El Khouri EC; Dokoupilova E; Vargas JI; Stanislavchuk M; Kellner H; Baranova E; Matsunaga N; Alten R
    Arthritis Res Ther; 2019 Dec; 21(1):281. PubMed ID: 31831079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
    Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P; Suh CH; Weinblatt ME; Smolen JS; Keystone EC; Genovese M; Vencovsky J; Kay J; Hong E; Baek Y; Ghil J
    Scand J Rheumatol; 2020 Sep; 49(5):361-370. PubMed ID: 32468892
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).
    Nam JL; Villeneuve E; Hensor EM; Conaghan PG; Keen HI; Buch MH; Gough AK; Green MJ; Helliwell PS; Keenan AM; Morgan AW; Quinn M; Reece R; van der Heijde DM; Wakefield RJ; Emery P
    Ann Rheum Dis; 2014 Jan; 73(1):75-85. PubMed ID: 23912798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
    Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
    Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2023 Mar; 82(2):114-122. PubMed ID: 34228181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.